DEvelopment oF a T14 Inhibitor for Treatment of ColoRectal Cancer (DEFIT-CRC)

Poster European Corner

Nom i cognoms / Name and surname

Raquel Boqué Sastre

Afiliació / Affiliation

Xenopat – Parc Científic de Barcelona

Programa de finançament europeu en que s’enmarca aquest projecte? / European funding programme in which this project is being carried out?

EU support (FP7, H2020, etc.) other than MSCA

 Títol del projecte / Project title

DEvelopment oF a T14 Inhibitor for Treatment of ColoRectal Cancer (DEFIT-CRC)

 Número del projecte / Project number


Breu explicació del projecte / Brief explanation of your project

DEFIT-CRC stems from a prior collaboration between two companies: Neuro-Bio (Abingdon, UK), which develops inhibitory drugs against T14 peptide for Alzheimer’s, and Xenopat (Barcelona, Spain), which offers the use of orthoxenograft® (the most reliable in vivo system to transfer drug effect results to the clinic) for drug development. They detected that T14 was overexpressed in metastatic colorectal cancer tissues. Building on that, DEFIT-CRC aims at developing a new antitumor and/or antimetastatic drug for patients with colorectal cancer.

 Enllaç a la pàgina web del projecte / Link to your project website

Repte en que s’emmarca aquest projecte / Challenge within the framework of this project

2. Cancer: working with Europe’s Beating Cancer Plan to improve the lives of more than 3 million people by 2030 through prevention, cure and solutions to live longer and better



Amb el suport de:

Amb el finançament de:

Aquest projecte està cofinançat pel programa de recerca i innovació Horizon Europe de la Unió Europea sota el projecte NitRecerCat (101061189).

This project is co-funded by the European Union’s research and innovation programme Horizon Europe, under the project NitRecercat (101061189).